The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...
BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...
RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ...
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral ...
The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.
In a recent study published in the Science Bulletin, researchers comprehensively examined the composition and phenotypic features of myeloid cells in human failing hearts at a single-cell level, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results